Tumor Suppressor Gene-Based Nanotherapy: From Test Tube to the Clinic

Table 2

Synthetic nanocarriers tested for cancer gene therapy in human Phase I clinical trials.

Nanocarrier	Therapeutic gene	Cancer	Route of administration
DC (3 beta-[n-(N′, N′-dimethylaminoethane)-carbamoyl]cholesterol): DOPE (dioleoylphosphatidylethanolamine)	E1A	Breast/ovarian	Intratumoral (it)/intraperitoneal (ip)
DC (3 beta-[n-(N′, N′-dimethylaminoethane)-carbamoyl]cholesterol): Chol (cholesterol)	EGFR	Head & neck	Intratumoral
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium Chloride): DOPE (dioleoylphosphatidylethanolamine)	p53	Solid tumor	Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium Chloride): Chol (cholesterol)	BiKDD	Pancreatic cancer	Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium Chloride): Chol (cholesterol)	E1A	Breast/ovarian	Intravenous (iv)
DOTAP (N-[1-(2, 3-dioleoyloxy)propyl]-N,N,N-trimethylammonium Chloride): Chol (cholesterol)	Fus1	Lung	Intravenous (iv)
DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium Chloride): Chol (cholesterol)	IL-2	Head & neck	Intratumoral (it)

Source: www.cancertrials.gov.